Derivation Web

source_c4ee507bb7ba4337

by researka:v2 · 2026-06-24 17:51:59.708872+04:00

{"publication_id": "a1f46e6e-cd1b-40a7-8641-5b96e4526923", "traces": [{"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "This paper synthesizes evidence on Berberine hydrochloride across 35 accepted source papers and 1902 high-confidence extracted claims.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "The evidence profile contains 6 direct clinical sources, 26 adjacent clinical sources, and 3 mechanistic or model-system sources, with a high-density pairwise disagreement map across the evidence base.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Positive study-level signals are summarized in the cardiometabolic outcome class, null signals in the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "The conclusion is that Berberine hydrochloride remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Population aging has become the central demographic story of the twenty-first century, and the question of whether pharmacological or nutraceutical interventions can extend the years spent in good health, rather than merely add years of disability, is now a defining question for biomedical research. The clinical stakes are concrete: cardiometabolic disease, type 2 diabetes, hepatic steatosis, sarcopenia, and immune dysfunction each impose massive morbidity, and they cluster in the same aging individuals with a frequency that has been proposed, but not proven, to reflect a shared underlying biology. The geroscience hypothesis, articulated in recent years, holds that targeting the biology of aging itself may produce larger and more simultaneous gains in healthspan than treating each chronic disease in isolation. The question of whether a single, accessible, low-cost molecule such as berberine can act on multiple age-related pathways in humans, and whether such an effect, if real, would translate into functional or hard-outcome benefit, remains the central unresolved issue that motivates the present synthesis. Berberine has been examined in more than three dozen recent clinical and pre-clinical reports catalogued in our evidence base, and yet the field has not converged on whether the drug's mechanistic plausibility is matched by clinically meaningful human evidence. The geroprotective agenda, in short, has been proposed, but the case for berberine as a geroscience intervention has not been built on a foundation of rigorous human outcome data, leaving a wide gap between expectation and proof. Against this backdrop, the present synthesis is timed to a literature that has expanded rapidly in the last five years, with both randomized trials and mechanistic studies accumulating faster than narrative reviews can absorb them.", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "The geroscience intervention logic rests on the proposition that aging hallmarks, including metabolic dysregulation, mitochondrial inefficiency, chronic low-grade inflammation, and altered intercellular signaling, are causally upstream of the chronic diseases of older adults. If a single agent can engage several of these hallmarks simultaneously, the case for repurposing it as a geroprotector becomes tractable in principle, even when the agent is not a novel targeted biologic. Berberine has been proposed, in this framing, as a candidate multi-target agent because it modulates AMPK signaling, mitochondrial function, lipid handling, and inflammatory cascades in pre-clinical models, and the mechanistic literature has been reviewed extensively. The alternative to the geroscience logic is the traditional one-disease-one-drug model, in which a molecule is tested for its effect on a single diagnostic entity, and the case for any broader anti-aging claim must then be built indirectly by aggregating across disease-specific trials. Most of the human evidence on berberine in our evidence base has been generated under the traditional model, examining glycemic control, lipid profiles, hepatic steatosis, or anthropometric outcomes, and the cross-disease aggregation required to make an anti-aging argument is precisely the kind of inference that warrants caution. The repurposing question, whether the geroscience framing adds value beyond what the disease-specific trials establish, is the second major theme of this synthesis. We do not attempt to resolve the question here, but rather to characterize the evidence on which the question rests, separating direct human data from indirect mechanistic extrapolation.", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Berberine is a plant-derived isoquinoline alkaloid, registered in the evidence base here as a nutritional supplement rather than a pharmaceutical, and this regulatory classification has shaped both the clinical literature and the translational debate around the compound. Mechanistic and pre-clinical work has examined β-cell redifferentiation (Xing 2025), biofilm-mediated resistance (Wang 2025), pancreatic adenocarcinoma growth (Ruan 2024), and inflammatory pathways relevant to arthritogenic viral infection (Seteyen 2023), suggesting broad receptor and pathway activity. The accessibility of berberine as a non-prescription product, combined with the breadth of the mechanistic literature, has made it attractive in popular and clinical discourse as a candidate geroprotector, but the gap between supplement-style regulatory status and geroscience-style evidence expectations remains a defining tension in the field. The question of whether the supplement's regulatory status can, or should, support a clinical anti-aging claim is therefore the third unresolved issue this synthesis must address.", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Several unresolved questions cut across the evidence base and structure the remaining sections of this synthesis. First, the mechanism-to-function translation problem: pre-clinical models of β-cell redifferentiation, AMPK activation, and inflammatory suppression have not been tied to functional human outcomes with sufficient granularity, and the inferential leap from rodent molecular biology to clinical anti-aging benefit remains wide. Second, the tradeoff problem: berberine's effect direction in pooled cardiometabolic syntheses is generally positive, but a recent multi-center randomized trial in diabetes-free individuals with obesity and MASLD reported a negative effect on the primary adiposity outcome (Lei 2026), and this null-versus-negative tension within the same broad outcome class has not been adjudicated. Third, the population specificity problem: meta-analyses of berberine in type 2 diabetes report pooled effects that may be driven by a subset of trials in patients with specific baseline characteristics, and it is unclear whether the average treatment effect generalizes to non-diabetic older adults, the population most relevant to a healthspan claim. Fourth, the duration and dose-response problem: the trial durations in the present base are short, the daily doses vary across reports, and the minimum effective exposure for any hard-outcome benefit, if one exists, has not been established. Fifth, the safety and comorbidity problem: although meta-analyses such as Nie 2024 have examined hepatic and metabolic safety, the long-term tolerability of berberine in older adults on multiple medications has not been characterized at geroscience-trial scale. Sixth, the surrogate-endpoint validity problem raised by methodological work on surrogate markers (Ioannidis 2005): pooled movement in lipid and glycemic surrogates does not, in general, guarantee hard-outcome benefit, and the present literature relies heavily on such surrogates. These six questions are not independent, and the synthesis attempts to handle them in parallel rather than in series, recognizing that a clean resolution of any one would still leave the geroprotective question incompletely answered.", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Geroscience reframes chronic disease research around the biological hallmarks of aging rather than single-organ pathology, arguing that interventions targeting shared upstream drivers of aging — mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence, epigenetic drift, and altered intercellular communication — could yield multi-domain benefits ( as cited in the geroscience literature). Within this framework, nutraceutical candidates such as berberine have attracted attention precisely because preclinical work suggests pleiotropic activity across several of these hallmarks, including AMPK activation and modulation of mitochondrial respiration. The regulatory implications are nontrivial: if berberine is repositioned as a geroprotector rather than a single-disease therapy, trial endpoints must shift from narrow surrogate readouts (HbA1c, LDL-C, liver enzymes) to composite or functional outcomes relevant to older adults, and clinical hold time must accommodate the long latency of aging-related endpoints (Ioannidis 2005). Trial designs that retain only cardiometabolic or hepatic biomarkers risk under-detecting either benefit or harm in the very domains geroscience claims to address, and this gap between biomarker-driven evidence and hard clinical outcome evidence is a recurring methodological theme in the field. Framing berberine within geroscience therefore obliges reviewers to separate mechanistic plausibility from confirmed human benefit, and to flag where the human evidence base is dominated by surrogate-endpoint RCTs rather than morbidity, mortality, or functional-status trials. This scoping review treats the geroscience framing as a hypothesis-generating lens rather than an established clinical indication, given the present state of the human evidence.", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Several methodological questions dominate the interpretation of the current berberine evidence base. First, endpoint selection is heavily skewed toward surrogate biomarkers — glycemic indices, lipid fractions, hepatic enzymes, anthropometric measures, and inflammatory markers — rather than hard outcomes such as myocardial infarction, stroke, hepatic decompensation, or mortality, which raises well-known concerns about surrogate-to-hard-outcome validity (Ioannidis 2005). Second, the mechanism-to-clinic gap is large: preclinical reports describe modulation of inflammatory cytokines, pancreatic β-cell redifferentiation, hepatic PPAR-pathway effects, and biofilm-mediated resistance (Seteyen 2023, P < 0.001; Ruan 2024, P < 0.05; Xing 2025; Zhang 2024; Wang 2025, P < 0.01), but clinical confirmation of these pathways at comparable effect sizes remains limited. Third, treatment durations of 9–24 weeks in most RCTs are short relative to the chronicity of cardiometabolic disease and the latency anticipated for any geroprotector effect, leaving open questions about durability, tolerance, and late-emerging safety signals. Fourth, concurrent interventions are common in the included trials — lifestyle counseling in prediabetes cohorts (Panigrahi 2023), probiotic co-administration in T2D (Wang 2021), curcumin co-administration in IBS (Wade 2024), antipsychotic co-therapy in schizophrenia (Chan 2022), and exercise training in middle-aged men with prediabetes (Nikseresht 2024) — making it difficult to isolate the berberine-specific contribution. Sixth, comparison against the established HbA1c target of 7% (ADA 2024) and the tighter 6.5% target (ADA 2024) reveals that the modest HbA1c reductions seen in many berberine meta-analyses (e. For example, Zhao 2023's −4.48 mmol/mol pooled estimate) may be clinically meaningful only in selected subgroups, and the directional signal in Lei 2026 for adiposity outcomes in diabetes-free adults suggests that the magnitude and direction of berberine's effects may depend heavily on baseline metabolic status. Across the corpus, these considerations motivate a structured evidence map in which direct RCTs, indirect observational cohorts, and mechanistic preclinical studies are analyzed on their own terms before any cross-domain synthesis is attempted.", "claim_id": "claim_12"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.", "claim_id": "claim_13"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.", "claim_id": "claim_14"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, mechanism, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_15"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_16"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |", "claim_id": "claim_17"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "| Contextual Adjacent Evidence | n=13; claims=541 | no extracted directional signal in 11/13 sources | 2 direct; 9 indirect; 2 review | limited corpus depth in this outcome class |", "claim_id": "claim_18"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.", "claim_id": "claim_19"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Contextual Adjacent Evidence: n=13; claims=541; no extracted directional signal in 11/13 sources | directness: 2 direct; 9 indirect; 2 review; main limitation: directionally heterogeneous.", "claim_id": "claim_20"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "The cardiometabolic evidence base draws on four direct randomized controlled trials and multiple systematic reviews/meta-analyses spanning type 2 diabetes, prediabetes, polycystic ovary syndrome, obesity, schizophrenia, and dyslipidemia populations.", "claim_id": "claim_21"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Pooled estimates from the systematic-review layer converge on clinically relevant improvements. Zhang 2008 reported P = 0.001 for the insulin-sensitization endpoint assessed by hyperinsulinemic-euglycemic clamp. The per-study × endpoint numeric matrix is provided in the evidence synthesis; readers are referred there for the complete tuple list across all 35 citations.", "claim_id": "claim_22"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Mechanistically, the clinical RCTs and pooled human evidence align with preclinical and indirect human observations linking berberine to AMPK activation, LDL-receptor upregulation, and improvements in insulin sensitivity, adipokine balance, and postprandial lipid handling. Bandala 2024 reported significant decreases in body weight, blood pressure, and Vis/Ap adipokine gene expression with concurrent increases in Ome (P < 0.05).", "claim_id": "claim_23"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Additional corpus sources included animal/preclinical evidence; the positive-direction pooled reviews Guo 2021 and Zhang 2008 (positive on cardiometabolic) are in agreement at the effect-direction level, but conflict with null-direction evidence from Bandala 2024, Shadin 2026, Rondanelli 2021, Wang 2021, Nikseresht 2024, and Miao 2025.", "claim_id": "claim_24"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Additional corpus sources included animal/preclinical evidence; by contrast, the direct clinical RCTs Panigrahi 2023, Li 2013, and Chan 2022 sit at a different directness tier from indirect or review-level sources and should not be aggregated with them; the indirectness-gap tensions are most pronounced between the Chan 2022 antipsychotic-weight-gain trial and Bandala 2024/Nikseresht 2024, and between Panigrahi 2023 and the dyslipidemia, glycemic, and metabolic-syndrome pooled reviews (Liu 2025, Shadin 2026, Zhao 2021, Rondanelli 2021, Guo 2021, Wang 2021, Zhang 2008, Blais 2023, Hernandez 2024, Zhao 2023, Miao 2025).", "claim_id": "claim_25"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "In a clinical RCT meta-analysis (Lu 2022) pooling randomized controlled trials in Chinese adults with metabolic syndrome and related disorders, berberine supplementation was evaluated against inflammatory biomarker endpoints including C-reactive protein (CRP), with the trial population, design, dose ranges, and follow-up windows abstracted from the constituent RCTs as detailed in the evidence synthesis. The pooled synthesis was constructed across trials of varying duration and berberine dosing, and the endpoint family was restricted to circulating inflammatory markers rather than clinical immune-mediated events. Per-study p-values recorded in the source (P < 0.05, P = 0.11, P < 0.10, P = 0.27, P = 0.35, P > 0.05, P = 0.46, P = 0.43) indicate a mixture of significant and non-significant biomarker effects across contributing trials.", "claim_id": "claim_26"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Additional corpus sources included animal/preclinical evidence; a within-corpus tension in the immune outcome class is the directness gap between Lu 2022 (direct, A1) and Liu 2024b (indirect) on immune endpoints, where the clinical RCT meta-analysis provides direct human evidence on systemic inflammatory markers while the nanoparticle study provides indirect, formulation-specific mechanistic evidence on a mucosal disease model. These differences should not be conflated, because the indirect Liu 2024b evidence pertains to a nanoparticle formulation and a colitis model rather than to oral berberine in metabolic syndrome adults.", "claim_id": "claim_27"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "In Seteyen 2023, when compared to ONNV-infected untreated cells, chloroquine significantly decreased downstream inflammatory readouts, and berberine was assessed within the same alkaloid panel; the source reports significance at P < 0.001, P < 0.01, P < 0.05, and P < 0.0001 across the reported contrasts. Ruan 2024 reports P < 0.05, P < 0.01, and P < 0.001 across in vitro and in vivo inflammation-related gene and proliferation endpoints in the PAAD model.", "claim_id": "claim_28"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "No within-corpus tension was flagged for the immune inflammation outcome class, because the two available studies do not form a non-orthogonal pair in the cross-study disagreement map; they address different pathogens, tissues, and inflammation readouts, and both report statistically supported effects at the source-traced thresholds. As a result, the disagreement that the broader synthesis surfaces (cross-study disagreements across outcome classes) does not localize to this section. The present subsection should therefore be read as a description of two concordant preclinical signals rather than as a contested evidence base, and any clinical extrapolation would require human RCT data not represented in the immune inflammation sources (Seteyen 2023; Ruan 2024).", "claim_id": "claim_29"}, {"candidate_sources": [{"doi": "10.1007/s10787-022-00976-2", "study": "The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials", "url": "https://doi.org/10.1007/s10787-022-00976-2"}, {"doi": "10.1186/s12978-021-01207-7", "study": "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis", "url": "https://doi.org/10.1186/s12978-021-01207-7"}, {"doi": "10.1186/s12902-023-01442-y", "study": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial", "url": "https://doi.org/10.1186/s12902-023-01442-y"}, {"doi": "10.3389/fphar.2025.1572197", "study": "Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials", "url": "https://doi.org/10.3389/fphar.2025.1572197"}, {"doi": "10.1155/2021/2074610", "study": "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": "https://doi.org/10.1155/2021/2074610"}], "claim": "Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.", "claim_id": "claim_30"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "a1f46e6e-cd1b-40a7-8641-5b96e4526923",
  "researka_submission_id": "6f0113a2-1cfe-44a3-9477-90e14d164f8b",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/a1f46e6e-cd1b-40a7-8641-5b96e4526923/sidecars/citation_traces.json"
}